

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/579,357
				Filing Date	May 16, 2006
				First Named Inventor	Reinhard BOLLI
				Art Unit	1644
				Examiner Name	Yunsoo KIM
Sheet	1	of	1	Attorney Docket Number	06478.1507-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		H. LILIE, "Folding of the Fab fragment within the intact antibody," <i>FEBS Lett.</i> 417: 239-242 (1997).	
		M.O. SPYCHER et al., "Well-tolerated liquid intravenous immunoglobulin G preparations (IVIg) have a low immunoglobulin G dimer (IgG-dimer) content," <i>J. Autoimmun.</i> 96 (Suppl. 1): 96 (1996).	
		R. BOLLI et al., "IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds," <i>J. Autoimmun.</i> 96 (Suppl. 1): 96 (1996).	
		M. CRAMER et al., "Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen®) stabilized with L-proline," <i>Vox Sanguinis</i> 96: 219-225 (2009).	
		G. LEMM, "Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy," <i>Neurology</i> 59(Suppl. 6): S28-S32 (2002).	
		W. WANG, "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <i>Int. J. Pharmaceutics</i> 185: 129-188 (1999).	
		B. ALBERTS et al., <i>Molecular Biology of the Cell</i> 3 rd Ed. 1994, cover pages and p. G-12.	
		A.K. ABBAS et al., <i>Cellular and Molecular Immunology</i> 4 th Ed. 2000, cover pages and pp. 470 and 482.	

Examiner Signature	/Yunsoo Kim/	Date Considered	05/11/2010
--------------------	--------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.K./